UK MODERN SLAVERY ACT DISCLOSURE
This statement is made in accordance with Section 54 of the Modern Slavery Act 2015 for BioCryst UK Limited (“BioCryst UK”).
Our Organisation
BioCryst UK is part of the Neopharmed Gentili S.p.A. group following the
acquisition of BioCryst’s European ORLADEYO® business. Neopharmed Gentili is a leading Italian
pharmaceutical company focused on high-value therapeutic areas, including specialty and rare
diseases, and expanding its commercial footprint across Europe. BioCryst UK supports the
commercialisation and promotion of orphan and rare-disease medicinal products, including ORLADEYO®,
through medical, regulatory and commercial activities in line with UK laws and industry standards.
Our Commitment
We are committed to conducting business ethically, lawfully, and with
respect for human rights. All employees must comply with the group Code of Conduct and Ethics, which
prohibits any form of forced labour, exploitation or human trafficking. Concerns may be raised
confidentially or anonymously via a supplier Compliance Hotline, with all reports investigated
appropriately.
Due Diligence Measures
During the reporting period we worked to strengthen supplier screening and oversight, including:
- Our supply chain’s implementation of World-Check One screening for new suppliers, assessing them against more than 3,200 global lists (sanctions, law-enforcement, regulatory, PEP and other risk categories).
- Clear expectations that suppliers comply with all applicable modern slavery and labour laws and with the Code of Conduct.
- Ongoing engagement with key suppliers, including business and quality-related interactions, to help maintain visibility of working conditions.
- The ability to restrict or terminate relationships where concerns cannot be adequately addressed.
Training and Awareness
We worked with our primary supplier to expanded awareness through Forced Labor Awareness training, delivered live to the Supply Chain function within our supply chain and made available via ComplianceWire.
Continuous Improvement
We remain committed to enhancing our approach through:
- ongoing risk-based supplier assessments;
- integration of due diligence outputs into procurement decisions;
- updated contractual standards; and
- continued employee training.
Our Position
BioCryst UK has a zero-tolerance approach to modern slavery, forced labour and
human trafficking within our organisation and our supply chains. We will continue to take steps to
identify, prevent and address these risks.
Approved by the Board of Directors of BioCryst UK Limited on 8 December 2025

Luke Robinson
General Manager